These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38907948)

  • 1. Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059.
    Wu JH; Pennesi E; Bautista F; Garrett M; Fukuhara K; Brivio E; Ammerlaan ACJ; Locatelli F; van der Sluis IM; Rossig C; Chen-Santel C; Bielorai B; Petit A; Starý J; Díaz-de-Heredia C; Rives S; O'Marcaigh A; Rizzari C; Engstler G; Nysom K; Rubio-San-Simón A; Bruno B; Bertrand Y; Brethon B; Rialland F; Plat G; Dirksen U; Sramkova L; Zwaan CM; Huitema ADR
    Clin Pharmacokinet; 2024 Jul; 63(7):981-997. PubMed ID: 38907948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
    Kantarjian HM; DeAngelo DJ; Stelljes M; Liedtke M; Stock W; Gökbuget N; O'Brien SM; Jabbour E; Wang T; Liang White J; Sleight B; Vandendries E; Advani AS
    Cancer; 2019 Jul; 125(14):2474-2487. PubMed ID: 30920645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma.
    Garrett M; Ruiz-Garcia A; Parivar K; Hee B; Boni J
    J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):211-222. PubMed ID: 30859374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc-concentration modelling.
    Hibma JE; Kantarjian HM; DeAngelo DJ; Boni JP
    Br J Clin Pharmacol; 2019 Mar; 85(3):590-600. PubMed ID: 30536405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inotuzumab Ozogamicin: First Pediatric Approval.
    Dhillon S
    Paediatr Drugs; 2024 Jul; 26(4):459-467. PubMed ID: 38780741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22
    Pennesi E; Brivio E; Ammerlaan ACJ; Jiang Y; Van der Velden VHJ; Beverloo HB; Sleight B; Locatelli F; Brethon B; Rossig C; Engstler G; Nilsson A; Bruno B; Petit A; Bielorai B; Rizzari C; Rialland F; Rubio-San-Simón A; Sirvent FJB; Diaz-de-Heredia C; Rives S; Zwaan CM
    Haematologica; 2024 Oct; 109(10):3157-3166. PubMed ID: 38186333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
    Kantarjian HM; Stock W; Cassaday RD; DeAngelo DJ; Jabbour E; O'Brien SM; Stelljes M; Wang T; Paccagnella ML; Nguyen K; Sleight B; Vandendries E; Neuhof A; Laird AD; Advani AS
    Clin Cancer Res; 2021 May; 27(10):2742-2754. PubMed ID: 33602684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study).
    Brivio E; Locatelli F; Lopez-Yurda M; Malone A; Díaz-de-Heredia C; Bielorai B; Rossig C; van der Velden VHJ; Ammerlaan ACJ; Thano A; van der Sluis IM; den Boer ML; Chen Y; Sleight B; Brethon B; Nysom K; Sramkova L; Øra I; Vinti L; Chen-Santel C; Zwaan CM
    Blood; 2021 Mar; 137(12):1582-1590. PubMed ID: 33067614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.
    Badar T; Szabo A; Dinner S; Liedtke M; Burkart M; Shallis RM; Yurkiewicz IR; Kuo E; Khan MA; Balasubramanian S; Yang J; Hefazi M; Podoltsev N; Patel A; Curran E; Wang A; Arslan S; Aldoss I; Siebenaller C; Mattison RJ; Litzow MR; Wadleigh M; Advani AS; Atallah E
    Cancer; 2021 Apr; 127(7):1039-1048. PubMed ID: 33259056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia.
    Proskorovsky I; Su Y; Fahrbach K; Vandendries E; Pagé V; Onyekwere U; Wang Y; Cappelleri JC; Stelljes M
    Adv Ther; 2019 Aug; 36(8):2147-2160. PubMed ID: 31140123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia.
    Contreras CF; Higham CS; Behnert A; Kim K; Stieglitz E; Tasian SK
    Pediatr Blood Cancer; 2021 Jan; 68(1):e28718. PubMed ID: 33098744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States.
    Delea TE; Zhang X; Amdahl J; Boyko D; Dirnberger F; Campioni M; Cong Z
    Pharmacoeconomics; 2019 Sep; 37(9):1177-1193. PubMed ID: 31218655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial.
    Jabbour E; Ravandi F; Kebriaei P; Huang X; Short NJ; Thomas D; Sasaki K; Rytting M; Jain N; Konopleva M; Garcia-Manero G; Champlin R; Marin D; Kadia T; Cortes J; Estrov Z; Takahashi K; Patel Y; Khouri MR; Jacob J; Garris R; O'Brien S; Kantarjian H
    JAMA Oncol; 2018 Feb; 4(2):230-234. PubMed ID: 28859185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.
    Kantarjian HM; DeAngelo DJ; Advani AS; Stelljes M; Kebriaei P; Cassaday RD; Merchant AA; Fujishima N; Uchida T; Calbacho M; Ejduk AA; O'Brien SM; Jabbour EJ; Zhang H; Sleight BJ; Vandendries ER; Marks DI
    Lancet Haematol; 2017 Aug; 4(8):e387-e398. PubMed ID: 28687420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Recurrent Refractory Pediatric Pre-B Acute Lymphoblastic Leukemia Using Inotuzumab Ozogamicin Monotherapy Resulting in CD22 Antigen Expression Loss as a Mechanism of Therapy Resistance.
    Paul MR; Wong V; Aristizabal P; Kuo DJ
    J Pediatr Hematol Oncol; 2019 Nov; 41(8):e546-e549. PubMed ID: 30807395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL.
    Kirchhoff H; Karsli U; Schoenherr C; Battmer K; Erschow S; Talbot SR; Steinemann D; Heuser M; Heidenreich O; Hilfiker-Kleiner D; Ganser A; Eder M; Scherr M
    Blood; 2021 May; 137(19):2657-2661. PubMed ID: 33512436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations.
    Rubinstein JD; O'Brien MM
    Front Immunol; 2023; 14():1237738. PubMed ID: 37600823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis.
    Stelmach P; Wethmar K; Groth C; Wenge DV; Albring J; Mikesch JH; Schliemann C; Reicherts C; Berdel WE; Lenz G; Stelljes M
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e724-e733. PubMed ID: 32646833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
    Jabbour E; Gökbuget N; Advani A; Stelljes M; Stock W; Liedtke M; Martinelli G; O'Brien S; Wang T; Laird AD; Vandendries E; Neuhof A; Nguyen K; Dakappagari N; DeAngelo DJ; Kantarjian H
    Leuk Res; 2020 Jan; 88():106283. PubMed ID: 31790983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of CD22 expression and expansion of a CD22
    Reinert J; Beitzen-Heineke A; Wethmar K; Stelljes M; Fiedler W; Schwartz S
    Ann Hematol; 2021 Nov; 100(11):2727-2732. PubMed ID: 34331563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.